Table 1. BCLC staging, management options, and survival.
BCLC: Barcelona clinical liver cancer; BSC: best supportive care; HCC: hepatocellular carcinoma; PS: performance status; TACE: transarterial chemoembolization
| Hepatocellular carcinoma | ||||
| Very early stage (0) | Early stage (A) | Intermediate stage (B) | Advanced stage (C) | Terminal stage (D) |
| Single <2 cm | Single or <3 nodules each <3 cm | Multinodular | Portal invasion and/or extrahepatic spread | Any tumor burden |
| Child-Pugh A | Child-Pugh A-B | Child-Pugh A-B | Child-Pugh A-B | Child-Pugh B-C |
| PS 0 | PS 0 | PS 0 | PS 1-2 | PS 3-4 |
| Ablation/resection/transplantation | TACE | Systemic therapy | BSC | |
| Survival >5 years | Survival >2.5 years | Survival 2 years | Survival 3 months | |